Advertisement

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study

Allison Barraclough, Musa Alzahrani, Marianne Schmidt Ettrup, Mark Bishton, Chris van Vliet, Pedro Farinha, Clare Gould, Simone Birch, Laurie H. Sehn, Vishakha Sovani, Mitchell Steven Ward, Bradley Augustson, Jorne Biccler, Joseph M. Connors, David W. Scott, Maher K. Gandhi, Kerry J. Savage, Tarec El-Galaly, Diego Villa and Chan Yoon Cheah

Article Information

Citation 
vol. 3 no. 13 2013-2021
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted January 15, 2019
  • Accepted May 9, 2019
  • Published online July 8, 2019.


Contributors 
  • Allison Barraclough, 1Department of Haematology, Sir Charles Gairdner Hospital, Perth, WA, Australia;2Department of Haematology, PathWest QEII Medical Centre WA, Perth, WA, Australia;3Department of Haematology, Austin Health, Melbourne, VIC, Australia;
  • Musa Alzahrani, 4Department of Hematology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada;5Faculty of Medicine, King Saud University, Riyadh, Saudi Arabia;
  • Marianne Schmidt Ettrup, 6Department of Pathology, Aalborg University Hospital, Aalborg, Denmark;
  • Mark Bishton, 7Department of Haematology, Nottingham City Hospital, Nottingham, United Kingdom;
  • Chris van Vliet, 8Department of Anatomical Pathology, PathWest QEII Medical Centre WA, Perth, WA, Australia;
  • Pedro Farinha, 9Department of Pathology and Laboratory Medicine and Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada;
  • Clare Gould, 10Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, QLD, Australia;
  • Simone Birch, 11Department of Anatomical Pathology, Pathology Queensland, Princess Alexandra Hospital, Brisbane, QLD, Australia;
  • Laurie H. Sehn, 12Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada;
  • Vishakha Sovani, 13Haematology Malignancy Diagnostic Service, Nottingham City Hospital, Nottingham, United Kingdom;
  • Mitchell Steven Ward, 1Department of Haematology, Sir Charles Gairdner Hospital, Perth, WA, Australia;14Hollywood Private Hospital, Perth, WA, Australia;
  • Bradley Augustson, 1Department of Haematology, Sir Charles Gairdner Hospital, Perth, WA, Australia;2Department of Haematology, PathWest QEII Medical Centre WA, Perth, WA, Australia;14Hollywood Private Hospital, Perth, WA, Australia;
  • Jorne Biccler, 15Department of Haematology, Aalborg University Hospital, Aalborg, Denmark;
  • Joseph M. Connors, 12Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada;
  • David W. Scott, 12Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada;
  • Maher K. Gandhi, 16University of Queensland Diamantina Institute, Brisbane, QLD, Australia;17Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia; and
  • Kerry J. Savage, 12Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada;
  • Tarec El-Galaly, 15Department of Haematology, Aalborg University Hospital, Aalborg, Denmark;
  • Diego Villa, 12Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada;
  • Chan Yoon Cheah, 1Department of Haematology, Sir Charles Gairdner Hospital, Perth, WA, Australia;2Department of Haematology, PathWest QEII Medical Centre WA, Perth, WA, Australia;14Hollywood Private Hospital, Perth, WA, Australia;18Department of Haematology, Medical School, University of Western Australia, Perth, WA, Australia

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output